Benzinga··Globe NewswireLilly Acquires Curevo for $1.5B to Bolster Next-Gen Shingles Vaccine Pipeline
Eli Lilly acquires Curevo for $1.5B to develop amezosvatein, a shingles vaccine with superior tolerability versus current treatments in Phase 2 trials.
LLYacquisitionbiotech